Cefiderocol and the Need for Higher-Quality Evidence: Methods Matter for Patients.
Saved in:
| Title: | Cefiderocol and the Need for Higher-Quality Evidence: Methods Matter for Patients. |
|---|---|
| Authors: | Epling BP; Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Powers JH 3rd; Clinical Research Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA. |
| Source: | Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2022 Aug 16; Vol. 66 (8), pp. e0076622. Date of Electronic Publication: 2022 Jul 18. |
| Publication Type: | Letter; Comment |
| Journal Info: | Publisher: American Society for Microbiology Country of Publication: United States NLM ID: 0315061 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1098-6596 (Electronic) Linking ISSN: 00664804 NLM ISO Abbreviation: Antimicrob Agents Chemother Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1098-6596 |
|---|---|
| DOI: | 10.1128/aac.00766-22 |
